7517 POSTER Clinical tolerability of trabectedin administered by two different schedules (weekly for 3 of 4 weeks vs q3 weeks) in patients with advanced/metastatic liposarcoma or leiomyosarcoma (L-sarcomas) progressing despite prior treatment with at least anthracycline and ifosfamide

S.Chawla; P.G.Casali; M.von Mehren; A.Le Cesne; J.Y.Blay; C.Lebedinsky; V.Alfaro; Y.Elsayed; B.Michiels; G.D.Demetri

首页> 外文期刊>European Journal of Cancer Supplements >7517 POSTER Clinical tolerability of trabectedin administered by two different schedules (weekly for 3 of 4 weeks vs q3 weeks) in patients with advanced/metastatic liposarcoma or leiomyosarcoma (L-sarcomas) progressing despite prior treatment with at least anthracycline and ifosfamide

【24h】

7517 POSTER Clinical tolerability of trabectedin administered by two different schedules (weekly for 3 of 4 weeks vs q3 weeks) in patients with advanced/metastatic liposarcoma or leiomyosarcoma (L-sarcomas) progressing despite prior treatment with at least anthracycline and ifosfamide

机译：7517 POSTER尽管已经接受了至少蒽环类和异环磷酰胺的治疗，但进展期/转移性脂肪肉瘤或平滑肌肉肉瘤（L-肉瘤）的患者，通过两种不同的方案（每周一次，连续4周中的3周vs第3周）给予曲贝汀的临床耐受性

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
S.Chawla; P.G.Casali; M.von Mehren; A.Le Cesne; J.Y.Blay; C.Lebedinsky; V.Alfaro; Y.Elsayed; B.Michiels; G.D.Demetri;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献

1. 7512 POSTER Assessing the clinical impact of trabectedin in patients with leiomyosarcomas or liposarcomas (L-sarcomas) progressing despite prior conventional chemotherapy: clinical benefit rate, growth modulation index and tumor variation as parameters of treatment effect in a randomised international trial of two trabectedin dosing regimens [J] . A.Le Cesne, M.von Mehren, S.Chawla, European Journal of Cancer Supplements . 2007,第4期

机译：7512 POSTER评估特拉贝汀对平滑肌肉瘤或脂肪肉瘤（L-肉瘤）患者的临床影响，尽管已有常规常规化学疗法：在两种特拉贝汀给药方案的随机国际试验中，临床获益率，生长调节指数和肿瘤变异作为治疗效果的参数
2. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. [J] . Demetri GD, Chawla SP, von Mehren M Journal of Clinical Oncology . 2009,第25期

机译：既往蒽环类药物和异环磷酰胺治疗失败后晚期或转移性脂肪肉瘤或平滑肌肉瘤患者中曲贝汀的疗效和安全性：两项不同方案的II期随机研究结果。
3. 7500 ORAL Impact of independent review on efficacy outcomes in a randomised multicenter trial of trabectedin given by two dosing regimens in patients (pts) with progressing leiomyosarcomas or liposarcomas (L-sarcomas) [J] . G.D.Demetri, S.Schuetze, A.Le Cesne, European Journal of Cancer Supplements . 2007,第4期

机译：7500口服在两种进行中的平滑肌肉瘤或脂肪肉瘤（L-肉瘤）患者中的两种给药方案中，独立审查对曲布汀的随机多中心试验的疗效结果的影响
4. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma [O] . R L Jones, G D Demetri, S M Schuetze, -1

机译：曲贝汀在老年肉瘤患者中的疗效和耐受性：III期亚组分析曲贝汀或达卡巴嗪在晚期脂肪肉瘤或平滑肌肉瘤患者中的随机对照研究
5. Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma--Comparison to Standard Dosing Schedule of 4-Weeks-on and 2-Weeks-off [O] . T. Kondo, T. Takagi, H. Kobayashi, 2014

机译：在转移性肾细胞癌患者患者中，Sunitinib的改变剂量调节时间表的卓越性耐受性 - 与标准给药时间表4周内，of 4周和2周休息

7517 POSTER Clinical tolerability of trabectedin administered by two different schedules (weekly for 3 of 4 weeks vs q3 weeks) in patients with advanced/metastatic liposarcoma or leiomyosarcoma (L-sarcomas) progressing despite prior treatment with at least anthracycline and ifosfamide

著录项

引文网络

相似文献

相关主题

期刊订阅